DE60132798D1 - Zusammensetzung einer natriumkanal-blockierenden verbindung - Google Patents

Zusammensetzung einer natriumkanal-blockierenden verbindung

Info

Publication number
DE60132798D1
DE60132798D1 DE60132798T DE60132798T DE60132798D1 DE 60132798 D1 DE60132798 D1 DE 60132798D1 DE 60132798 T DE60132798 T DE 60132798T DE 60132798 T DE60132798 T DE 60132798T DE 60132798 D1 DE60132798 D1 DE 60132798D1
Authority
DE
Germany
Prior art keywords
sodium channel
composition
blocking compound
channel blocking
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60132798T
Other languages
English (en)
Other versions
DE60132798T2 (de
Inventor
Yuhong Kang
Frank Haykong Shum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wex Medical Ltd
Original Assignee
Nanning Maple Leaf Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanning Maple Leaf Pharmaceutical Co Ltd filed Critical Nanning Maple Leaf Pharmaceutical Co Ltd
Publication of DE60132798D1 publication Critical patent/DE60132798D1/de
Application granted granted Critical
Publication of DE60132798T2 publication Critical patent/DE60132798T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60132798T 2000-11-22 2001-11-19 Zusammensetzung einer natriumkanal-blockierenden verbindung Expired - Lifetime DE60132798T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN00132672 2000-11-22
CNB001326724A CN1236773C (zh) 2000-11-22 2000-11-22 用于镇痛、麻醉或治疗药物依赖性的制剂
PCT/CN2001/001566 WO2002041915A1 (en) 2000-11-22 2001-11-19 A composition of sodium channel blocking compound

Publications (2)

Publication Number Publication Date
DE60132798D1 true DE60132798D1 (de) 2008-03-27
DE60132798T2 DE60132798T2 (de) 2009-02-12

Family

ID=4595311

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60132798T Expired - Lifetime DE60132798T2 (de) 2000-11-22 2001-11-19 Zusammensetzung einer natriumkanal-blockierenden verbindung

Country Status (8)

Country Link
US (1) US6559154B2 (de)
EP (2) EP1930027A3 (de)
JP (1) JP2004513186A (de)
CN (1) CN1236773C (de)
AT (1) ATE385799T1 (de)
AU (1) AU2002221491A1 (de)
DE (1) DE60132798T2 (de)
WO (1) WO2002041915A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1284536C (zh) * 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
MXPA04004543A (es) 2001-11-15 2005-03-31 Micro Algae Corp Composiciones farmaceuticas que contienen 3,4-propinoperhidropurinas y sus usos para el bloqueo de la transmision neuronal.
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
AU2005244096B2 (en) * 2004-05-07 2011-03-17 Algenis Spa Transdermal administration of phycotoxins
AU2005244105B2 (en) * 2004-05-07 2011-10-06 Algenis Spa Phycotoxins and uses thereof
AU2005287511A1 (en) * 2004-09-21 2006-03-30 Wex Medical Limited Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain
EP1799220A1 (de) * 2004-09-22 2007-06-27 Laboratorios del Dr. Esteve S.A. Tetrodotoxin und derivate davon zur behandlung von periphernervöser neuropathischer schmerzen
EP1853628B1 (de) * 2005-02-17 2015-08-19 Vertex Pharmaceuticals Incorporated Spleissvariante der alpha-untereinheit des typ iii natriumkanals
WO2007025212A2 (en) * 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
CA2619668A1 (en) * 2005-08-25 2007-03-01 Edge Renfeng Wang Use of sodium channel blockers for the management of musculoskeletal pain
US7972813B2 (en) * 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
US20080200408A1 (en) * 2005-09-30 2008-08-21 Mccormack Kenneth Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
CN103271920A (zh) * 2006-03-27 2013-09-04 威克斯医药有限公司 钠通道阻滞剂治疗由于化疗而产生的神经病理性疼痛的用途
US8658699B2 (en) 2008-05-19 2014-02-25 Massachusetts Institute Of Technology Chemical permeation enhancers enhance nerve blockade by toxins
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
US8957207B2 (en) 2009-03-24 2015-02-17 Proteus S.A. Methods for producing phycotoxins
NZ710890A (en) 2013-03-15 2016-11-25 Childrens Medical Ct Corp Neosaxitoxin combination formulations for prolonged local anesthesia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029793A (en) 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US3898339A (en) * 1973-08-14 1975-08-05 Astra Pharma Prod Spinal anesthesia using small amounts of tetrodotoxin or desoxytetrodotoxin
US4022899A (en) 1973-06-12 1977-05-10 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
EP0750909B1 (de) * 1994-03-17 2002-12-11 Nanning Maple Leaf Pharmaceutical Co., Ltd. Verwendung von amino-hydrierten chinazolinverbindungen und ihren derivaten zur entwöhnung bei drogenabhängigkeit
CN1081034C (zh) * 1997-03-07 2002-03-20 潘心富 一种双胍基氢化嘌呤环类化合物的戒毒药
US6030974A (en) * 1997-04-02 2000-02-29 The Regents Of The University Of California Method of anesthesia
WO1998051290A2 (en) * 1997-05-16 1998-11-19 Children's Medical Center Corporation Local anesthetic formulations comprising a site 1 sodium channel blocker combined with a second active agent
CN1240702C (zh) 2000-09-18 2006-02-08 威克斯医药有限公司 高获得率提取替曲朵辛的方法
CN1203857C (zh) * 2000-09-18 2005-06-01 威克斯医药有限公司 局部麻醉与镇痛的新方法
CN1284536C (zh) 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用

Also Published As

Publication number Publication date
WO2002041915A1 (en) 2002-05-30
CN1236773C (zh) 2006-01-18
EP1930027A2 (de) 2008-06-11
JP2004513186A (ja) 2004-04-30
AU2002221491A1 (en) 2002-06-03
EP1335747B1 (de) 2008-02-13
DE60132798T2 (de) 2009-02-12
ATE385799T1 (de) 2008-03-15
US6559154B2 (en) 2003-05-06
US20020119987A1 (en) 2002-08-29
CN1353990A (zh) 2002-06-19
EP1335747A1 (de) 2003-08-20
EP1335747A4 (de) 2005-10-12
EP1930027A3 (de) 2008-06-18

Similar Documents

Publication Publication Date Title
ATE385799T1 (de) Zusammensetzung einer natriumkanal-blockierenden verbindung
PT1413582E (pt) Pirrolobenzodiazepinas dimericas
DK1301436T3 (da) Fremgangsmåder til syntese af et oxidationsmiddel samt dets anvendelse
HN1999000125A (es) Nuevos derivados sustituidos del pirazol
PL360092A1 (en) Structures and compositions increasing the stability of peroxide actives
NO20034660D0 (no) Spiropyrazolforbindelser
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
DK1040119T3 (da) Hemiasterlinanaloger
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
HK1029754A1 (en) Formulations for protection of peg-interferon alpha conjugates.
DE60112960D1 (de) Kondensierte pyridoindolderivate
BG106316A (en) Ambroxol-containing lozenge
HUP0202592A2 (hu) Lazofoxifen transzdermális adagolása
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
BG105964A (en) C(10) carbonate substituted taxanes and their use as antitumor agents
BR0114065A (pt) Triazolo-epotilonas
DK1177191T3 (da) Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
GT199900037A (es) Nuevas composiciones herbicidas.
DK1052995T3 (da) Farmaceutisk præparat til nasal indgivelse af thiocolchicosid
DE50003634D1 (de) SPRAY, ENTHALTEND UBICHINON Qn
SE9901062D0 (sv) Use for conifer sapling protection
BR8002856U (pt) Televisão relógio
BR0113202A (pt) Compostos de trioxepano
YU30198A (sh) Prečišćavanje propilen oksida
ATE282611T1 (de) Stolonoxide

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: WEX PHARMACEUTICALS INC., VANCOUVER, BRITISH C, CA

8327 Change in the person/name/address of the patent owner

Owner name: WEX MEDICAL LTD., WANCHAI, HK